Skip to content

Help people live a life of higher quality

New generation of prescription medicines derived from synthetic cannabinoid acids

Learn about our treatments

EPM is developing prescription medicines, based on novel discoveries of synthetic cannabinoid acids to address unmet patient needs in a wide range of therapeutic conditions. These innovations represent new treatment options for the pharmaceutical industry.

Learn more about us

EPM unlocks the true potential of cannabinoid acids.

Learn about our science

About Us

EPM is a patient-focused Pharmaceutical group.

EPM develops prescription medicines derived from synthetic cannabinoid acids to address unmet patient needs.

Our mission is to develop safer treatment options for people.

Our focus is to bring cannabinoid acid based medicines to patients in a wide range of therapeutic conditions, current treatment developments include Psoriasis, IBD and ARDS. At EPM we care to make a real difference by helping people live a life of higher quality.

EPM created a pipeline which includes the discovery of 14 protected synthetic molecules, including 8 novel structures and the development of various processes.

The development of EPM’s molecules starts in Prof. Raphael Mechoulam’s laboratory at the Hebrew University, who co-founded EPM together with Reshef Swisa and Asaf Ohana, one of Israel first treated patients with CBD and an experienced cannabinoids entrepreneur.

EPM maintains control over all aspects of the product development process – research and discovery, formulation, toxicology, scaleup manufacturing, clinical trial and regulatory affairs.

EPM is leading the way in realizing the untapped potential of cannabinoids acids as new pharmaceutical treatments.

Our Leadership